Physician
Salisbury Pediatric Associates PA
Salisbury Pediatric Associates PA was paid $25.79M by Medicaid between Jan 2018 and Dec 2024, across 102 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 26% of everything it billed.
33Billing provider infoSALISBURY PEDIATRIC ASSOCIATES PA
SALISBURY, NC 28144
SALISBURY, NC 28144
33aNPI1598862732assigned 09/20/2006
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$25.79M
24GClaims1,230,152
24DCodes billed102
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in North Carolina
Rank by total paid#1 of 20
Median peer was paid$4.16M
This provider vs. median6.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 82,262 | $2.67M | |
| 2019 | 92,398 | $3.03M | |
| 2020 | 64,874 | $2.47M | |
| 2021 | 151,064 | $3.50M | |
| 2022 | 260,018 | $4.55M | |
| 2023 | 299,243 | $4.97M | |
| 2024incomplete | 280,293 | $4.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 75,842 | 67,044 | $6.68M |
| 99199 | Unlisted special service, procedure or report | 19% | 667,701 | 353,584 | $4.81M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 72,441 | 62,944 | $4.36M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.0% | 21,245 | 18,578 | $1.81M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.7% | 17,047 | 15,571 | $1.46M |
| 99050 | 4.7% | 49,201 | 43,469 | $1.20M | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.3% | 13,030 | 11,719 | $1.11M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.4% | 22,604 | 18,919 | $872K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.9% | 8,311 | 7,073 | $740K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.0% | 26,428 | 25,472 | $517K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.5% | 13,301 | 12,918 | $398K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 20,675 | 18,902 | $191K |
90 more codes
| D0145 | Oral evaluation for a patient under three years of age | <1% | 5,614 | $188K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,302 | $185K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13,877 | $179K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 12,183 | $158K |
| 99401 | <1% | 4,652 | $138K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 831 | $88K |
| 87070 | <1% | 9,038 | $88K | |
| D1206 | Topical application of fluoride varnish | <1% | 5,617 | $83K |
| 92551 | <1% | 28,151 | $55K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,183 | $44K |
| 90474 | <1% | 2,173 | $44K | |
| 90837 | Psychotherapy session, about an hour | <1% | 401 | $39K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 594 | $36K |
| 96127 | <1% | 9,007 | $35K | |
| 99460 | <1% | 473 | $34K | |
| 90651 | <1% | 1,141 | $28K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 758 | $26K |
| 99173 | <1% | 30,778 | $23K | |
| 83655 | <1% | 1,291 | $17K | |
| 90686 | <1% | 12,257 | $13K | |
| 90734 | <1% | 725 | $13K | |
| 81025 | <1% | 1,622 | $11K | |
| 0002A | <1% | 193 | $10K | |
| 99462 | <1% | 291 | $9K | |
| 94375 | <1% | 348 | $9K | |
| 0001A | <1% | 172 | $8K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 860 | $7K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 52 | $7K |
| 0071A | <1% | 126 | $5K | |
| 96160 | <1% | 1,859 | $5K | |
| 90461 | <1% | 347 | $5K | |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | <1% | 76 | $4K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 29 | $3K |
| 90785 | <1% | 2,822 | $3K | |
| 87807 | <1% | 174 | $2K | |
| 90633 | <1% | 3,130 | $2K | |
| 0072A | <1% | 38 | $2K | |
| 90619 | <1% | 557 | $2K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 27 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 112 | $2K |
| 96156 | <1% | 49 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 112 | $1K |
| 99464 | <1% | 25 | $1K | |
| 99070 | <1% | 200 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 132 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 435 | $1K |
| 81000 | <1% | 289 | $1K | |
| 90671 | <1% | 1,278 | $665.40 | |
| 90715 | <1% | 181 | $488.09 | |
| 90670 | <1% | 7,345 | $460.77 | |
| 94664 | <1% | 40 | $400.68 | |
| 85014 | <1% | 141 | $297.63 | |
| 96150 | <1% | 61 | $268.17 | |
| 90656 | <1% | 732 | $185.67 | |
| 90698 | <1% | 9,668 | $108.07 | |
| 86308 | <1% | 16 | $102.08 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 186 | $100.00 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 82 | $96.97 |
| 91307 | <1% | 381 | $87.64 | |
| 90744 | <1% | 2,379 | $76.60 | |
| 36416 | <1% | 2,064 | $41.08 | |
| 90621 | <1% | 46 | $4.25 | |
| 94760 | <1% | 31 | $2.17 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 64 | $1.30 |
| 1031F | 0% | 214 | $0.00 | |
| 90680 | 0% | 4,287 | $0.00 | |
| 90716 | 0% | 2,061 | $0.00 | |
| 99000 | 0% | 5,168 | $0.00 | |
| 90696 | 0% | 522 | $0.00 | |
| 3008F | 0% | 10,247 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 311 | $0.00 |
| 2015F | 0% | 373 | $0.00 | |
| 2016F | 0% | 369 | $0.00 | |
| 2030F | 0% | 229 | $0.00 | |
| 2001F | 0% | 127 | $0.00 | |
| 4056F | 0% | 140 | $0.00 | |
| 90677 | 0% | 853 | $0.00 | |
| 4058F | 0% | 140 | $0.00 | |
| 1038F | 0% | 25 | $0.00 | |
| 4140F | 0% | 12 | $0.00 | |
| 90685 | 0% | 714 | $0.00 | |
| 90707 | 0% | 2,175 | $0.00 | |
| 4124F | 0% | 4,197 | $0.00 | |
| 3210F | 0% | 541 | $0.00 | |
| 4120F | 0% | 243 | $0.00 | |
| 1039F | 0% | 78 | $0.00 | |
| 91300 | 0% | 406 | $0.00 | |
| 90713 | 0% | 12 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 26 | $0.00 |
| J7610 | Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLINS, MARK (PRESIDENT)